LncRNA LINC01857 promotes cell growth and diminishes apoptosis via PI3K/mTOR pathway and EMT process by regulating miR-141-3p/MAP4K4 axis in diffuse large B-cell lymphoma

LINC01857 has been proven to be involved in glioma and breast cancer. However, the biological function of LINC01857 in diffuse large B-cell lymphoma (DLBCL) is poorly investigated. By accessing to the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTE X ), LINC01857 expression was found...

Full description

Saved in:
Bibliographic Details
Published in:Cancer gene therapy 2021-09, Vol.28 (9), p.1046-1057
Main Authors: Li, Qian, Li, Bao, Lu, Chang-Liang, Wang, Jing-Ye, Gao, Min, Gao, Wei
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
38
42/109
42/41
45
631/67
631/67/395
82/80
Apoptosis
B-cell lymphoma
Bioinformatics
Biomedical and Life Sciences
Biomedicine
Breast cancer
Care and treatment
Cell Culture Techniques
Cell cycle
Cell growth
Cell Proliferation
Cellular signal transduction
Development and progression
Epithelial-Mesenchymal Transition - immunology
Flow cytometry
Gene Expression
Gene Therapy
Genetic aspects
Genomes
Genotypes
Glioma
Health aspects
Humans
Lymphocytes B
Lymphoma
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Large B-Cell, Diffuse - pathology
MicroRNAs - metabolism
Non-Hodgkin's lymphomas
Phosphatidylinositol 3-Kinases - metabolism
Protein kinases
RNA
RNA, Long Noncoding - metabolism
TOR protein
TOR Serine-Threonine Kinases - metabolism
Transfection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:LINC01857 has been proven to be involved in glioma and breast cancer. However, the biological function of LINC01857 in diffuse large B-cell lymphoma (DLBCL) is poorly investigated. By accessing to the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTE X ), LINC01857 expression was found upregulated in both DLBCL tissues and cells. Cell proliferation and flow cytometry assays showed that LINC01857 promoted proliferation and cell cycle, but suppressed apoptosis in DLBCL cells. Bioinformatics analysis and luciferase reporter assay confirmed that LINC01857 may serve as a sponge for miR-141-3p and miR-141-3p may target MAP4K4. Mechanically, the regulatory action of miR-141-3p/MAP4K4 on DLBCL cellular behaviors was regulated by LINC01857. In addition, LINC01857 could increase the activity of PI3K/mTOR pathway and facilitate the EMT process in a miR-141-3p-mediated manner in DLBCL. Our data illustrated that the LINC01857/miR-141-3p/MAP4K4 might function as a promising therapeutic avenue for DLBCL treatment.
ISSN:0929-1903
1476-5500
DOI:10.1038/s41417-020-00267-4